EdgarLookup

Core Scientific, Inc./tx — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Core Scientific, Inc./tx filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Financials Insiders
-90.5%
Profit Margin
Net income ÷ revenue
-12.3%
Return on Assets
Net income ÷ assets
-3.44x
Debt-to-Equity
Total liabilities ÷ equity
-37.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $319.02M Mar 2, 2026
FY2025 Dec 31, 2024 $510.67M Mar 2, 2026
FY2025 Dec 31, 2023 $502.40M Mar 2, 2026
FY2024 Dec 31, 2022 $640.31M Mar 2, 2026
FY2023 Dec 31, 2021 $544.48M Mar 13, 2024
FY2022 Dec 31, 2020 $60.32M Apr 4, 2023

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($288.62M) Mar 2, 2026
FY2024 Dec 31, 2024 ($291.15M) Mar 2, 2026
FY2024 Sep 30, 2024 ($1.15B) Mar 2, 2026
FY2024 Jun 30, 2024 ($902.16M) Mar 2, 2026
FY2025 Dec 31, 2023 ($246.49M) Mar 2, 2026
FY2024 Dec 31, 2022 ($2.15B) Mar 2, 2026
FY2023 Dec 31, 2021 $47.31M Mar 13, 2024
FY2021 Dec 31, 2020 ($10.4K) Mar 30, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($245.59M) Mar 2, 2026
FY2024 Dec 31, 2024 ($65.39M) Mar 2, 2026
FY2024 Sep 30, 2024 ($76.67M) Mar 2, 2026
FY2024 Jun 30, 2024 ($90.68M) Mar 2, 2026
FY2025 Dec 31, 2023 $8.96M Mar 2, 2026
FY2024 Dec 31, 2022 ($2.11B) Mar 2, 2026
FY2023 Dec 31, 2021 $131.49M Mar 13, 2024
FY2021 Dec 31, 2020 ($10.4K) Mar 30, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.35B Mar 2, 2026
FY2025 Dec 31, 2024 $1.48B Mar 2, 2026
FY2024 Sep 30, 2024 $824.59M Mar 2, 2026
FY2024 Jun 30, 2024 $664.20M Mar 2, 2026
FY2024 Dec 31, 2023 $712.16M Mar 2, 2026
FY2023 Dec 31, 2022 $807.69M Mar 13, 2024
FY2022 Dec 31, 2021 $2.44B Apr 4, 2023
FY2021 Dec 31, 2020 $15.0K Mar 30, 2022

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.31B Mar 2, 2026
FY2025 Dec 31, 2024 $2.42B Mar 2, 2026
FY2024 Dec 31, 2023 $1.31B Mar 2, 2026
FY2023 Dec 31, 2022 $1.22B Mar 13, 2024
FY2022 Dec 31, 2021 $1.05B Apr 4, 2023
FY2021 Dec 31, 2020 $400 Mar 30, 2022

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($962.74M) Mar 2, 2026
FY2025 Dec 31, 2024 ($943.05M) Mar 2, 2026
FY2024 Sep 30, 2024 ($826.66M) Mar 2, 2026
FY2024 Jun 30, 2024 ($1.18B) Mar 2, 2026
FY2025 Dec 31, 2023 ($596.94M) Mar 2, 2026
FY2025 Dec 31, 2022 ($409.35M) Mar 2, 2026
FY2024 Dec 31, 2021 $1.34B Mar 2, 2026
FY2023 Dec 31, 2020 $89.22M Mar 13, 2024
FY2021 Dec 28, 2020 $0 Mar 30, 2022
FY2022 Dec 31, 2019 $106.33M Apr 4, 2023

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 2, 2026
FY2024 Dec 31, 2024 0 Mar 2, 2026
FY2024 Sep 30, 2024 (4) Mar 2, 2026
FY2024 Jun 30, 2024 (5) Mar 2, 2026
FY2025 Dec 31, 2023 0 Mar 2, 2026
FY2024 Dec 31, 2022 (6) Mar 2, 2026
FY2023 Dec 31, 2021 0 Mar 13, 2024
FY2022 Dec 31, 2020 0 Apr 4, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 2, 2026
FY2024 Dec 31, 2024 0 Mar 2, 2026
FY2024 Sep 30, 2024 (4) Mar 2, 2026
FY2024 Jun 30, 2024 (5) Mar 2, 2026
FY2025 Dec 31, 2023 0 Mar 2, 2026
FY2024 Dec 31, 2022 (6) Mar 2, 2026
FY2023 Dec 31, 2021 0 Mar 13, 2024
FY2022 Dec 31, 2020 0 Apr 4, 2023

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $311.38M Mar 2, 2026
FY2025 Dec 31, 2024 $836.20M Mar 2, 2026
FY2025 Dec 31, 2023 $50.41M Mar 2, 2026
FY2024 Dec 31, 2022 $15.88M Mar 2, 2026
FY2023 Dec 31, 2021 $117.87M Mar 13, 2024